Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nexalin Technology, Inc. (NXL)
USD0.48
+0.07 (+16.31%)
US NASDAQ Healthcare Medical - Devices
Address
1776 Yorktown 77056
Houston, TX, US
Houston, TX, US
CEO
Mark White
Website
nexalin.com
IPO
2022-09-16
CIK 1527352 ISIN US65345B2016
Also trades on
NASDAQ Capital Market · NXL (USD)
NASDAQ Capital Market · NXLIW (USD)
Description
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.48
+0.07 (+16.31%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
854.6K
Beta
3.84
Float Shares
16.33M
Free Float %
79.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.68% | -7.21% | -14.78% | -23.21% | -72.83% | -38.64% | -72.61% | -59.72% | -84.78% | -84.78% | -84.78% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
0.48
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-37.43
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+78.8% ★ Q1'26: -63.5% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+39.8% ★ Q1'26: +26.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-2,698.5% Q1'26: -11,787.7% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-2,781.7% Q1'26: -14,179.9% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-33,869.7% Q1'26: -4,769.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+77.9% Q1'26: +48.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
168.7K
est: 172.0K (-1.9%)
|
301.6K
est: 231.0K (+30.6%)
|
345.0K
345.0K – 345.0K
+49.4% YoY
|
690.0K
690.0K – 690.0K
+100.0% YoY
|
| EBITDA |
-7.74M
est: -172.0K (-4,399.7%)
|
-8.37M
est: -231.0K (-3,523.1%)
|
-345.0K
-345.0K – -345.0K
-49.4% YoY
|
-690.0K
-690.0K – -690.0K
-100.0% YoY
|
| EBIT |
-7.75M
est: -172.0K (-4,408.5%)
|
-8.39M
est: -231.0K (-3,532.4%)
|
-345.0K
-345.0K – -345.0K
-49.4% YoY
|
-690.0K
-690.0K – -690.0K
-100.0% YoY
|
| Net Income |
-7.61M
est: -10.00M (+23.9%)
|
-8.22M
est: -8.03M (-2.4%)
|
-5.74M
-5.74M – -5.74M
+28.6% YoY
|
-5.08M
-5.08M – -5.08M
+11.4% YoY
|
| SGA |
6.70M
est: 4.96M (+34.9%)
|
7.55M
est: 6.67M (+13.2%)
|
9.96M
9.96M – 9.96M
+49.4% YoY
|
19.91M
19.91M – 19.91M
+100.0% YoY
|
| EPS |
-0.83
est: -0.61 (-36.1%)
|
-0.50
est: -0.49 (-2.0%)
|
-0.35
-0.35 – -0.35
+28.6% YoY
|
-0.31
-0.31 – -0.31
+11.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-5.29M
OE per share TTM
-0.29
Owner's Yield
-75.78%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
0.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
6
Total invested
79.5K
Insider transactions (90d)
1
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
6
-13 vs prev Q
New positions
3
Closed positions
16
Increased
4
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | PEAK6 LLC | 476.5K +476.5K (+100.0%) | 265.9K +265.9K (+100.0%) | 2.68% +2.678 pp | 0.00% +0.001 pp | USD0.56 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 177.9K +1.3K (+0.8%) | 99.3K -62.6K (-38.7%) | 1.00% -0.124 pp | 0.00% +0.000 pp | USD2.22 -74.8% | 7 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 150.3K +28.5K (+23.4%) | 83.9K -27.9K (-25.0%) | 0.84% +0.070 pp | 0.00% +0.000 pp | USD1.09 -48.6% | 10 qtrs — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 122.1K +66.4K (+119.2%) | 68.1K +17.0K (+33.4%) | 0.69% +0.332 pp | 0.00% +0.000 pp | USD0.75 -25.3% | 3 qtrs — |
| 5 | VIRTU FINANCIAL LLC | 39.4K +39.4K (+100.0%) | 22.0K +22.0K (+100.0%) | 0.22% +0.222 pp | 0.00% +0.001 pp | USD0.56 +0.0% | 1 qtrs NEW |
| 6 | JANE STREET GROUP, LLC | 35.0K +5.5K (+18.6%) | 19.5K -7.6K (-27.9%) | 0.20% +0.009 pp | 0.00% +0.000 pp | USD0.86 -34.9% | 2 qtrs — |
| 7 | STATE STREET CORP | 32.3K +— (+0.0%) | 18.0K -11.6K (-39.2%) | 0.18% -0.024 pp | 0.00% +0.000 pp | USD2.19 -74.4% | 7 qtrs — |
| 8 | FMR LLC | 31.6K +30.2K (+2,158.9%) | 17.6K +16.4K (+1,274.4%) | 0.18% +0.169 pp | 0.00% +0.000 pp | USD0.57 -1.8% | 3 qtrs — |
| 9 | CITADEL ADVISORS LLC | 30.9K +30.9K (+100.0%) | 17.2K +17.2K (+100.0%) | 0.17% +0.174 pp | 0.00% +0.000 pp | USD0.56 +0.0% | 3 qtrs — |
| 10 | TWO SIGMA SECURITIES, LLC | 28.7K +28.7K (+100.0%) | 16.0K +16.0K (+100.0%) | 0.16% +0.161 pp | 0.00% +0.002 pp | USD0.56 +0.0% | 3 qtrs — |
| 11 | NORTHERN TRUST CORP | 24.1K +— (+0.0%) | 13.4K -8.7K (-39.2%) | 0.14% -0.018 pp | 0.00% +0.000 pp | USD2.39 -76.6% | 5 qtrs — |
| 12 | KOVACK ADVISORS, INC. | 23.3K +13.3K (+132.1%) | 13.0K +3.8K (+41.2%) | 0.13% +0.067 pp | 0.00% 0.000 pp | USD0.74 -24.3% | 3 qtrs — |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 18.9K -43.6K (-69.8%) | 10.5K -46.8K (-81.6%) | 0.11% -0.292 pp | 0.00% +0.000 pp | USD0.92 -39.1% | 2 qtrs — |
| 14 | UBS GROUP AG | 15.9K +15.5K (+3,513.9%) | 8.9K +8.5K (+2,101.7%) | 0.09% +0.087 pp | 0.00% +0.000 pp | USD0.57 -1.8% | 8 qtrs — |
| 15 | LPL FINANCIAL LLC | 10.5K +10.5K (+100.0%) | 5.8K +5.8K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.000 pp | USD0.56 +0.0% | 1 qtrs NEW |
| 16 | ADVISOR GROUP HOLDINGS, INC. | 2.4K +250.0 (+11.9%) | 1.3K -680.0 (-34.1%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD2.53 -77.9% | 7 qtrs — |
| 17 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.3K +907.0 (+63.4%) | 1.3K -8.0 (-0.6%) | 0.01% +0.004 pp | 0.00% +0.000 pp | USD0.95 -41.1% | 13 qtrs — |
| 18 | FARTHER FINANCE ADVISORS, LLC | 1.0K +— (+0.0%) | 558.00 -359.0 (-39.1%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD0.99 -43.4% | 3 qtrs — |
| 19 | BANK OF AMERICA CORP /DE/ | 145.00 +10.0 (+7.4%) | 81.00 -43.0 (-34.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.29 -56.6% | 7 qtrs — |
| 20 | KINGSVIEW WEALTH MANAGEMENT, LLC | — -10.0K (-100.0%) | — -9.2K (-100.0%) | 0.00% -0.064 pp | 0.00% 0.000 pp | USD— | 5 qtrs SOLD |
| 21 | CITIGROUP INC | — -88.0 (-100.0%) | — -81.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 22 | ROYAL BANK OF CANADA | — -3.0K (-100.0%) | — -3.0K (-100.0%) | 0.00% -0.019 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 23 | XTX TOPCO LTD | — -11.9K (-100.0%) | — -10.9K (-100.0%) | 0.00% -0.076 pp | 0.00% -0.001 pp | USD— | 5 qtrs SOLD |
| 24 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | — -1.5K (-100.0%) | — -1.4K (-100.0%) | 0.00% -0.010 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 25 | MYDA ADVISORS LLC | — -150.0K (-100.0%) | — -137.6K (-100.0%) | 0.00% -0.954 pp | 0.00% -0.030 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 75.4K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 | Van Fleet Justin | Officer | — | — | Stock Option (right to buy) | 65,217 | 1.15 | 75.0K | 0 | D | ↗ |
| 2025-12-19 | White Mark | Director / Officer | A-Award | A | Stock Option (right to buy)* | 1,000,000 | 0.83 | 830.0K | 2,387,024 | D | ↗ |
| 2025-12-19 | Van Fleet Justin | Officer | A-Award | A | Stock Option (right to buy)* | 100,000 | 0.83 | 83.0K | 230,435 | D | ↗ |
| 2025-12-19 | Shelton Carolyn Hamby | Officer | A-Award | A | Stock Option (right to buy)* | 100,000 | 0.83 | 83.0K | 210,620 | D | ↗ |
| 2025-12-19 | Owens David | Director / Officer | A-Award | A | Stock Option (right to buy)* | 1,000,000 | 0.83 | 830.0K | 2,484,809 | D | ↗ |
| 2025-12-19 | Kazden Alan | Director | A-Award | A | Stock Option (right to buy)* | 100,000 | 0.83 | 83.0K | 362,500 | D | ↗ |
| 2025-12-19 | Hu Ben | Director | A-Award | A | Stock Option (right to buy)* | 100,000 | 0.83 | 83.0K | 100,000 | D | ↗ |
| 2025-09-29 | Owens David | Director / Officer | A-Award | A | Common stock | 36,459 | 0.00 | — | 191,252 | D | ↗ |
| 2025-09-29 | OSSER LEONARD | 10% Owner | A-Award | A | Common Stock | 83,333 | 0.00 | — | 1,618,577 | D | ↗ |
| 2025-09-29 | Kazden Alan | Director | A-Award | A | Common stock | 36,459 | 0.00 | — | 119,590 | I | ↗ |
| 2025-09-29 | Hu Ben | Director | A-Award | A | Common stock | 36,459 | 0.00 | — | 377,095 | D | ↗ |
| 2025-09-12 | Shelton Carolyn Hamby | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 2.95 | 59.0K | 110,620 | D | ↗ |
| 2025-09-12 | Owens David | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 0.96 | 96.0K | 1,484,809 | D | ↗ |
| 2025-09-10 | Elson Marilyn | 10% Owner | S-Sale | D | Common Stock Warrants | 23,150 | 4.15 | 96.1K | 112,850 | D | ↗ |
| 2025-08-01 | Van Fleet Justin | Officer | — | — | Common Stock | 0 | 0.00 | — | 25,000 | D | ↗ |
| 2025-07-17 | Elson Marilyn | 10% Owner | A-Award | A | Stock Option (right to buy) | 30,000 | 1.15 | 34.5K | 436,000 | D | ↗ |
| 2025-03-12 | Shelton Carolyn Hamby | Officer | P-Purchase | A | Common Stock | 6,000 | 2.20 | 13.2K | 30,000 | I | ↗ |
| 2025-02-26 | White Mark | Director / Officer | A-Award | A | Stock Option (right to buy) | 939,597 | 0.89 | 840.0K | 1,387,024 | D | ↗ |
| 2025-02-26 | Owens David | Director / Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 2.95 | 368.8K | 919,184 | D | ↗ |
| 2025-02-04 | Owens David | Director / Officer | P-Purchase | A | Common stock | 1,000 | 3.10 | 3.1K | 155,793 | D | ↗ |
| 2025-01-28 | Owens David | Director / Officer | P-Purchase | A | Common stock | 1,500 | 2.70 | 4.1K | 153,793 | D | ↗ |
| 2025-01-23 | Owens David | Director / Officer | P-Purchase | A | Common stock | 1,000 | 2.70 | 2.7K | 152,293 | D | ↗ |
| 2025-01-13 | Owens David | Director / Officer | P-Purchase | A | Common stock | 2,000 | 2.50 | 5.0K | 151,293 | D | ↗ |
| 2024-12-31 | Shelton Carolyn Hamby | Officer | — | — | Common stock | 0 | 0.00 | — | 24,000 | D | ↗ |
| 2024-11-07 | Shelton Carolyn Hamby | Officer | A-Award | A | Stock Option (right to buy) | 90,620 | 0.66 | 60.0K | 90,620 | D | ↗ |
| 2024-11-07 | Owens David | Director / Officer | A-Award | A | Stock Option (right to buy) | 262,500 | 0.94 | 246.8K | 262,500 | D | ↗ |
| 2024-11-02 | Kazden Alan | Director | P-Purchase | A | Stock Option (right to buy) | 262,500 | 0.94 | 246.8K | 262,500 | D | ↗ |
| 2024-10-28 | Owens David | Director / Officer | P-Purchase | A | Common stock | 500 | 2.19 | 1.1K | 148,293 | D | ↗ |
| 2024-09-30 | Hu Ben | Director | A-Award | A | Common stock | 175,000 | 0.00 | — | 340,636 | D | ↗ |
| 2024-09-30 | Elson Marilyn | 10% Owner | A-Award | A | Common Stock | 700,000 | 0.00 | — | 1,535,244 | D | ↗ |
| 2024-09-30 | Bernhard Leslie | Director | A-Award | A | Common stock | 49,838 | 0.00 | — | 49,838 | D | ↗ |
| 2024-09-23 | Elson Marilyn | 10% Owner | A-Award | A | Common Stock | 700,000 | 0.00 | — | 1,535,244 | D | ↗ |
| 2024-08-13 | Owens David | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.95 | 950.00 | 147,793 | — | ↗ |
| 2024-06-28 | Owens David | Director / Officer | P-Purchase | A | Common stock | 1,000 | 1.75 | 1.8K | 146,793 | — | ↗ |
| 2024-06-18 | Owens David | Director / Officer | P-Purchase | A | Common stock | 1,619 | 0.71 | 1.1K | 145,793 | — | ↗ |
| 2024-06-10 | Owens David | Director / Officer | P-Purchase | A | Common stock | 1,000 | 0.62 | 620.00 | 144,174 | — | ↗ |
| 2022-09-28 | Elson Marilyn | Officer / 10% Owner | P-Purchase | A | Common stock warrants | 9,500 | 4.15 | 39.4K | 109,500 | — | ↗ |
| 2022-09-16 | White Mark | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 4.15 | 10.4K | 289,627 | — | ↗ |
| 2022-09-16 | Owens David | Director / Officer | P-Purchase | A | Common stock warrants | 2,500 | 4.15 | 10.4K | 2,500 | — | ↗ |
| 2022-09-16 | Morad Rick | Director | P-Purchase | A | Common Stock | 2,500 | 4.15 | 10.4K | 107,989 | — | ↗ |
| 2022-09-16 | Kazden Alan | Director | P-Purchase | A | Common stock warrants | 2,500 | 4.15 | 10.4K | 2,500 | — | ↗ |
| 2022-09-16 | Elson Marilyn | Officer / 10% Owner | P-Purchase | A | Common Stock | 36,000 | 4.15 | 149.4K | 825,744 | — | ↗ |
| 2022-09-15 | White Mark | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 4.15 | 103.8K | 309,127 | — | ↗ |
| 2022-09-15 | Morad Rick | Director | — | D | Common Stock | 0 | 0.00 | — | 105,841 | — | ↗ |
| 2022-09-15 | Hu Ben | Director | — | I | Common Stock | 0 | 0.00 | — | 3,582 | — | ↗ |
| 2022-09-15 | Elson Marilyn | Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 789,744 | — | ↗ |
| 2007-04-20 | WHITE GREGORY | Director | D-Return | D | Stock Option (right to buy) | 5,500 | 23.61 | 129.9K | 0 | — | ↗ |
| 2007-04-20 | SIEGEL STEVEN F | Officer | D-Return | D | Stock Option (right to buy) | 47,779 | 22.75 | 1.09M | 0 | — | ↗ |
| 2007-04-20 | MCCALL H CARL | Director | D-Return | D | Stock Option (right to buy) | 3,671 | 21.08 | 77.4K | 0 | — | ↗ |
| 2007-04-20 | ENGELMAN IRWIN | Director | D-Return | D | Stock Option (right to buy) | 3,671 | 21.08 | 77.4K | 0 | — | ↗ |
| 2007-04-20 | Carroll Michael A | Officer | D-Return | D | Stock Option (right to buy) | 55,250 | 25.05 | 1.38M | 0 | — | ↗ |
| 2007-04-04 | WHITE GREGORY | Director | U-Tender | D | Common Stock | 1,000 | 33.15 | 33.2K | 0 | — | ↗ |
| 2007-04-04 | SIEGEL STEVEN F | Officer | U-Tender | D | Common Stock | 34,047 | 33.15 | 1.13M | 0 | — | ↗ |
| 2007-04-04 | MCCALL H CARL | Director | U-Tender | D | Common Stock | 4,211 | 33.15 | 139.6K | 0 | — | ↗ |
| 2007-04-04 | ENGELMAN IRWIN | Director | U-Tender | D | Common Stock | 4,848 | 33.15 | 160.7K | 0 | — | ↗ |
| 2007-04-04 | Carroll Michael A | Officer | U-Tender | D | Common Stock | 100 | 33.15 | 3.3K | 0 | — | ↗ |
| 2007-03-16 | WHITE GREGORY | Director | A-Award | A | Common Stock | 150 | 0.00 | — | 9,768 | — | ↗ |
| 2007-03-16 | MCCALL H CARL | Director | A-Award | A | Common Stock | 150 | 0.00 | — | 4,211 | — | ↗ |
| 2007-03-16 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 150 | 0.00 | — | 4,848 | — | ↗ |
| 2007-02-27 | WHITE GREGORY | Director | A-Award | A | Common Stock | 2,000 | 30.03 | 60.1K | 9,618 | — | ↗ |
| 2007-02-27 | SIEGEL STEVEN F | Officer | A-Award | A | Stock Option (right to buy) | 20,830 | 30.03 | 625.5K | 20,830 | — | ↗ |
| 2007-02-27 | MCCALL H CARL | Director | A-Award | A | Common Stock | 1,300 | 30.03 | 39.0K | 4,061 | — | ↗ |
| 2007-02-27 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 1,300 | 30.03 | 39.0K | 4,698 | — | ↗ |
| 2007-02-27 | Carroll Michael A | Officer | A-Award | A | Common Stock | 9,990 | 30.03 | 300.0K | 46,597 | — | ↗ |
| 2007-01-04 | Carroll Michael A | Officer | M-Exempt | A | Common Stock | 3,000 | 13.71 | 41.1K | 36,586 | — | ↗ |
| 2006-12-28 | SIEGEL STEVEN F | Officer | M-Exempt | A | Common Stock | 5,681 | 17.60 | 100.0K | 31,454 | — | ↗ |
| 2006-12-18 | WHITE GREGORY | Director | A-Award | A | Common Stock | 180 | 0.00 | — | 7,581 | — | ↗ |
| 2006-12-18 | MCCALL H CARL | Director | A-Award | A | Common Stock | 180 | 0.00 | — | 2,730 | — | ↗ |
| 2006-12-18 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 180 | 0.00 | — | 3,398 | — | ↗ |
| 2006-09-18 | WHITE GREGORY | Director | A-Award | A | Common Stock | 181 | 0.00 | — | 7,367 | — | ↗ |
| 2006-09-18 | MCCALL H CARL | Director | A-Award | A | Common Stock | 181 | 0.00 | — | 2,522 | — | ↗ |
| 2006-09-18 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 181 | 0.00 | — | 3,218 | — | ↗ |
| 2006-08-25 | Carroll Michael A | Officer | S-Sale | D | Common Stock | 5,000 | 26.70 | 133.5K | 31,706 | — | ↗ |
| 2006-08-24 | Carroll Michael A | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 13.71 | 137.1K | 9,588 | — | ↗ |
| 2006-08-23 | Carroll Michael A | Officer | S-Sale | D | Common Stock | 5,000 | 26.50 | 132.5K | 31,706 | — | ↗ |
| 2006-08-08 | SIEGEL STEVEN F | Officer | S-Sale | D | Common Stock | 1,400 | 25.25 | 35.4K | 45,773 | — | ↗ |
| 2006-06-15 | WHITE GREGORY | Director | A-Award | A | Common Stock | 212 | 0.00 | — | 7,330 | — | ↗ |
| 2006-06-15 | MCCALL H CARL | Director | A-Award | A | Common Stock | 212 | 0.00 | — | 2,312 | — | ↗ |
| 2006-06-15 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 212 | 0.00 | — | 3,037 | — | ↗ |
| 2006-06-01 | WHITE GREGORY | Director | A-Award | A | Stock Option (right to buy) | 5,500 | 23.61 | 129.9K | 5,500 | — | ↗ |
| 2006-06-01 | MCCALL H CARL | Director | A-Award | A | Stock Option (right to buy) | 3,750 | 23.61 | 88.5K | 3,750 | — | ↗ |
| 2006-06-01 | ENGELMAN IRWIN | Director | A-Award | A | Stock Option (right to buy) | 3,750 | 23.61 | 88.5K | 3,750 | — | ↗ |
| 2006-05-09 | SIEGEL STEVEN F | Officer | S-Sale | D | Common Stock | 9,500 | 25.05 | 238.0K | 25,773 | — | ↗ |
| 2006-05-08 | SIEGEL STEVEN F | Officer | M-Exempt | A | Common Stock | 5,000 | 16.97 | 84.9K | 85,773 | — | ↗ |
| 2006-03-28 | Carroll Michael A | Officer | M-Exempt | A | Common Stock | 3,280 | 11.35 | 37.2K | 30,706 | — | ↗ |
| 2006-03-16 | WHITE GREGORY | Director | A-Award | A | Common Stock | 194 | 0.00 | — | 6,906 | — | ↗ |
| 2006-03-16 | MCCALL H CARL | Director | A-Award | A | Common Stock | 194 | 0.00 | — | 2,073 | — | ↗ |
| 2006-03-16 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 194 | 0.00 | — | 2,825 | — | ↗ |
| 2006-03-01 | SIEGEL STEVEN F | Officer | A-Award | A | Stock Option (right to buy) | 55,250 | 25.05 | 1.38M | 55,250 | — | ↗ |
| 2006-03-01 | Carroll Michael A | Officer | A-Award | A | Stock Option (right to buy) | 55,250 | 25.05 | 1.38M | 55,250 | — | ↗ |
| 2006-02-23 | Carroll Michael A | Officer | — | D | Stock Option (right to buy) | 34,100 | 25.69 | 876.0K | 0 | — | ↗ |
| 2005-12-31 | Carroll Michael A | Officer | — | I | Common Stock | 0 | 0.00 | — | 1,834 | — | ↗ |
| 2005-12-27 | Carroll Michael A | Officer | M-Exempt | A | Common Stock | 1,000 | 11.35 | 11.4K | 23,536 | — | ↗ |
| 2005-12-16 | WHITE GREGORY | Director | A-Award | A | Common Stock | 205 | 0.00 | — | 6,681 | — | ↗ |
| 2005-12-16 | MCCALL H CARL | Director | A-Award | A | Common Stock | 205 | 0.00 | — | 1,855 | — | ↗ |
| 2005-12-16 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 205 | 0.00 | — | 2,631 | — | ↗ |
| 2005-12-09 | SIEGEL STEVEN F | Officer | S-Sale | D | Common Stock | 4,500 | 24.27 | 109.2K | 21,783 | — | ↗ |
| 2005-09-27 | WHITE GREGORY | Director | J-Other | A | Stock Option (right to buy) | 485 | 17.77 | 8.6K | 4,235 | — | ↗ |
| 2005-09-27 | SIEGEL STEVEN F | Officer | J-Other | A | Stock Option (right to buy) | 4,534 | 16.97 | 76.9K | 39,534 | — | ↗ |
| 2005-09-27 | MCCALL H CARL | Director | J-Other | A | Stock Option (right to buy) | 421 | 21.08 | 8.9K | 3,671 | — | ↗ |
| 2005-09-27 | ENGELMAN IRWIN | Director | J-Other | A | Stock Option (right to buy) | 388 | 18.45 | 7.2K | 3,388 | — | ↗ |
| 2005-09-27 | Carroll Michael A | Officer | J-Other | A | Stock Option (right to buy) | 971 | 17.82 | 17.3K | 8,471 | — | ↗ |
| 2005-09-16 | WHITE GREGORY | Director | A-Award | A | Common Stock | 207 | 0.00 | — | 6,223 | — | ↗ |
| 2005-09-16 | MCCALL H CARL | Director | A-Award | A | Common Stock | 207 | 0.00 | — | 1,426 | — | ↗ |
| 2005-09-16 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 207 | 0.00 | — | 2,426 | — | ↗ |
| 2005-08-22 | Carroll Michael A | Officer | M-Exempt | A | Common Stock | 4,900 | 12.81 | 62.8K | 23,018 | — | ↗ |
| 2005-06-15 | WHITE GREGORY | Director | A-Award | A | Common Stock | 181 | 0.00 | — | 5,992 | — | ↗ |
| 2005-06-15 | MCCALL H CARL | Director | A-Award | A | Common Stock | 181 | 0.00 | — | 1,219 | — | ↗ |
| 2005-06-15 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 181 | 0.00 | — | 2,219 | — | ↗ |
| 2005-06-01 | WHITE GREGORY | Director | A-Award | A | Stock Option (right to buy) | 5,250 | 26.94 | 141.4K | 5,250 | — | ↗ |
| 2005-06-01 | MCCALL H CARL | Director | A-Award | A | Stock Option (right to buy) | 3,500 | 26.94 | 94.3K | 3,500 | — | ↗ |
| 2005-06-01 | ENGELMAN IRWIN | Director | A-Award | A | Stock Option (right to buy) | 3,500 | 26.94 | 94.3K | 3,500 | — | ↗ |
| 2005-03-16 | WHITE GREGORY | Director | A-Award | A | Common Stock | 190 | 0.00 | — | 5,786 | — | ↗ |
| 2005-03-16 | MCCALL H CARL | Director | A-Award | A | Common Stock | 190 | 0.00 | — | 1,038 | — | ↗ |
| 2005-03-16 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 190 | 0.00 | — | 2,038 | — | ↗ |
| 2005-03-02 | Carroll Michael A | Officer | — | D | Stock Option (right to buy) | 24,000 | 26.10 | 626.4K | 0 | — | ↗ |
| 2005-03-01 | Carroll Michael A | Officer | — | I | Common Stock | 0 | 0.00 | — | 80 | — | ↗ |
| 2005-02-23 | SIEGEL STEVEN F | Officer | A-Award | A | Common Stock | 5,440 | 0.00 | — | 21,783 | — | ↗ |
| 2004-12-16 | WHITE GREGORY | Director | A-Award | A | Common Stock | 136 | 0.00 | — | 5,576 | — | ↗ |
| 2004-12-16 | MCCALL H CARL | Director | A-Award | A | Common Stock | 136 | 0.00 | — | 848 | — | ↗ |
| 2004-12-16 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 136 | 0.00 | — | 1,848 | — | ↗ |
| 2004-12-10 | SIEGEL STEVEN F | Officer | M-Exempt | A | Common Stock | 5,000 | 15.48 | 77.4K | 31,343 | — | ↗ |
| 2004-12-01 | SIEGEL STEVEN F | Officer | M-Exempt | D | Stock Option (right to buy) | 3,600 | 12.81 | 46.1K | 48,270 | — | ↗ |
| 2004-11-15 | SIEGEL STEVEN F | Officer | M-Exempt | D | Stock Option (right to buy) | 5,000 | 12.81 | 64.1K | 51,870 | — | ↗ |
| 2004-09-16 | WHITE GREGORY | Director | A-Award | A | Common Stock | 149 | 0.00 | — | 5,422 | — | ↗ |
| 2004-09-16 | MCCALL H CARL | Director | A-Award | A | Common Stock | 149 | 0.00 | — | 712 | — | ↗ |
| 2004-09-16 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 149 | 0.00 | — | 1,712 | — | ↗ |
| 2004-09-09 | WHITE GREGORY | Director | F-InKind | D | Common Stock | 1,715 | 26.40 | 45.3K | 5,273 | — | ↗ |
| 2004-06-16 | WHITE GREGORY | Director | A-Award | A | Common Stock | 162 | 0.00 | — | 4,977 | — | ↗ |
| 2004-06-16 | MCCALL H CARL | Director | A-Award | A | Common Stock | 162 | 0.00 | — | 563 | — | ↗ |
| 2004-06-16 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 162 | 0.00 | — | 1,563 | — | ↗ |
| 2004-06-01 | WHITE GREGORY | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 23.81 | 119.1K | 5,000 | — | ↗ |
| 2004-06-01 | MCCALL H CARL | Director | A-Award | A | Stock Option (right to buy) | 3,250 | 23.81 | 77.4K | 3,250 | — | ↗ |
| 2004-06-01 | ENGELMAN IRWIN | Director | A-Award | A | Stock Option (right to buy) | 3,250 | 23.81 | 77.4K | 3,250 | — | ↗ |
| 2004-04-19 | SIEGEL STEVEN F | Officer | F-InKind | D | Common Stock | 237 | 23.55 | 5.6K | 16,343 | — | ↗ |
| 2004-03-16 | WHITE GREGORY | Director | A-Award | A | Common Stock | 143 | 0.00 | — | 4,806 | — | ↗ |
| 2004-03-16 | MCCALL H CARL | Director | A-Award | A | Common Stock | 143 | 0.00 | — | 401 | — | ↗ |
| 2004-03-16 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 143 | 0.00 | — | 1,401 | — | ↗ |
| 2004-03-10 | Carroll Michael A | Officer | — | D | Stock Option (right to buy) | 19,280 | 19.16 | 369.4K | 0 | — | ↗ |
| 2004-03-02 | SIEGEL STEVEN F | Officer | A-Award | A | Stock Option (right to buy) | 42,700 | 26.10 | 1.11M | 42,700 | — | ↗ |
| 2003-12-15 | WHITE GREGORY | Director | A-Award | A | Common Stock | 151 | 0.00 | — | 4,658 | — | ↗ |
| 2003-12-15 | MCCALL H CARL | Director | A-Award | A | Common Stock | 151 | 0.00 | — | 258 | — | ↗ |
| 2003-12-15 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 151 | 0.00 | — | 1,258 | — | ↗ |
| 2003-12-02 | SIEGEL STEVEN F | Officer | M-Exempt | A | Common Stock | 12,500 | 24.13 | 301.6K | 23,490 | — | ↗ |
| 2003-12-01 | SIEGEL STEVEN F | Officer | M-Exempt | D | Stock Option (right to buy) | 100,000 | 24.13 | 2.41M | 12,500 | — | ↗ |
| 2003-09-16 | WHITE GREGORY | Director | A-Award | A | Common Stock | 107 | 0.00 | — | 4,504 | — | ↗ |
| 2003-09-16 | MCCALL H CARL | Director | A-Award | A | Common Stock | 107 | 0.00 | — | 107 | — | ↗ |
| 2003-09-16 | ENGELMAN IRWIN | Director | A-Award | A | Common Stock | 107 | 0.00 | — | 1,107 | — | ↗ |
| 2003-08-27 | SIEGEL STEVEN F | Officer | S-Sale | D | Common Stock | 8,800 | 22.85 | 201.1K | 14,690 | — | ↗ |
| 2003-08-11 | SIEGEL STEVEN F | Officer | S-Sale | D | Common Stock | 2,200 | 22.76 | 50.1K | 33,790 | — | ↗ |
| 2003-07-29 | WHITE GREGORY | Director | M-Exempt | A | Common Stock | 2,000 | 21.38 | 42.8K | 6,328 | — | ↗ |
| 2003-06-13 | SIEGEL STEVEN F | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-06-02 | WHITE GREGORY | Director | A-Award | A | Stock Option (right to buy) | 4,750 | 20.83 | 98.9K | 4,750 | — | ↗ |
| 2003-06-02 | MCCALL H CARL | Director | A-Award | A | Stock Option (right to buy) | 3,000 | 20.83 | 62.5K | 3,000 | — | ↗ |
| 2003-06-02 | ENGELMAN IRWIN | Director | A-Award | A | Stock Option (right to buy) | 3,000 | 20.83 | 62.5K | 3,000 | — | ↗ |
| 2003-05-14 | MCCALL H CARL | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-05-14 | ENGELMAN IRWIN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-04-02 | Carroll Michael A | Officer | — | D | Stock Option (right to buy) | 37,120 | 19.99 | 742.0K | 0 | — | ↗ |
| 2002-03-19 | Carroll Michael A | Officer | — | D | Stock Option (right to buy) | 27,080 | 15.48 | 419.2K | 0 | — | ↗ |
| 2001-02-23 | Carroll Michael A | Officer | — | D | Stock Option (right to buy) | 8,690 | 12.81 | 111.3K | 0 | — | ↗ |
| 2000-05-19 | Carroll Michael A | Officer | — | D | Stock Option (right to buy) | 3,750 | 19.88 | 74.5K | 0 | — | ↗ |
| 1999-10-08 | Carroll Michael A | Officer | — | D | Stock Option (right to buy) | 7,500 | 20.13 | 150.9K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-14.0K
Shares Outstanding
20.58M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Mark White Chief Executive Officer/Chief Financial Officer David Owens, M.D. Chief Medical Officer Michael Nketiah Senior Vice-President of Quality, Clinical and Regulatory | — | — | 661.5K | — | — | 15.6K | 873.1K | 75.76% | ↗ |
| 2 | 2023 | Mark White Chief Executive Officer/Chief Financial Officer David Owens, M.D. Chief Medical Officer Michael Nketiah Senior Vice-President of Quality, Clinical and Regulatory | 250.0K | 30.0K | 10.5K | — | — | — | 290.5K | 3.60% | ↗ |
| 3 | 2022 | Mark White Chief Executive Officer Marilyn Elson Chief Financial Officer David Owens, M.D. Chief Medical Officer Michael Nketiah Senior Vice President of Quality, Regulatory and Clinical Affairs | 191.3K | — | — | — | — | — | 191.3K | 0.00% | ↗ |
| 4 | 2022 | Mark White Chief Executive Officer/Chief Financial Officer David Owens, M.D. Chief Medical Officer Michael Nketiah Senior Vice-President of Quality, Clinical and Regulatory | 191.3K | — | — | — | — | — | 191.3K | 0.00% | ↗ |
| 5 | 2021 | Mark White Chief Executive Officer Marilyn Elson Chief Financial Officer David Owens, M.D. Chief Medical Officer Michael Nketiah Senior Vice President of Quality, Regulatory and Clinical Affairs | — | — | 293.8K | — | — | — | 293.8K | 100.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark White | President, Chief Executive Officer & Director | 598.0K | male |
| Carolyn Shelton | Executive Vice President of Clinical, Quality & Regulatory Affairs | 340.0K | female |
| David Owens | Chief Medical Officer, Member of Scientific Advisory Board & Director | 50.6K | — |
| John Patrick Claude | Co-Founder and Director of Engineering & Development | — | male |
| Justin Van Fleet | Chief Financial Officer | — | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NXL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
